{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genotyping&page=19",
    "query": {
      "condition": "Genotyping",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 512,
    "total_pages": 52,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genotyping&page=20&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genotyping&page=18&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T18:43:52.947Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00377182",
      "title": "A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Copegus",
          "type": "DRUG"
        },
        {
          "name": "PEGASYS",
          "type": "DRUG"
        },
        {
          "name": "RO5024048 1500mg",
          "type": "DRUG"
        },
        {
          "name": "RO5024048 3000mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 107,
      "start_date": "2006-09",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-10-29T18:43:52.947Z",
      "location_count": 17,
      "location_summary": "La Jolla, California • Long Beach, California • Sacramento, California + 13 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00377182"
    },
    {
      "nct_id": "NCT01415141",
      "title": "Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Peginterferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "telaprevir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Vermont",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2011-07",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-10-29T18:43:52.947Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • Burlington, Vermont",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01415141"
    },
    {
      "nct_id": "NCT01310205",
      "title": "Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "SCV-07",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SciClone Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2010-08",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2012-03-08",
      "last_synced_at": "2026-10-29T18:43:52.947Z",
      "location_count": 4,
      "location_summary": "Anaheim, California • Louisville, Kentucky • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Washington",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01310205"
    },
    {
      "nct_id": "NCT01408121",
      "title": "African-American Pharmacogenetics",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Medstar Health Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2011-11",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2014-08-11",
      "last_synced_at": "2026-10-29T18:43:52.947Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01408121"
    },
    {
      "nct_id": "NCT02098616",
      "title": "Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "DCV/ASV/BMS-791325",
          "type": "DRUG"
        },
        {
          "name": "DCV/ASV/BMS-791325 + RBV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Timothy Morgan, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2014-07",
      "completion_date": "2016-02",
      "has_results": false,
      "last_update_posted_date": "2016-04-19",
      "last_synced_at": "2026-10-29T18:43:52.947Z",
      "location_count": 1,
      "location_summary": "Long Beach, California",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02098616"
    },
    {
      "nct_id": "NCT01465191",
      "title": "Effect of Mu-opioid Receptor Genetics on 3 Doses of Spinal Morphine for Postoperative Analgesia After Cesarean Section",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Postoperative Pain"
      ],
      "interventions": [
        {
          "name": "Morphine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 169,
      "start_date": "2011-11",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2020-12-10",
      "last_synced_at": "2026-10-29T18:43:52.947Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • New York, New York",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01465191"
    },
    {
      "nct_id": "NCT02293096",
      "title": "Pharmacogenetic Prediction of Metoprolol Effectiveness",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "metoprolol succinate",
          "type": "DRUG"
        },
        {
          "name": "Genotyping",
          "type": "GENETIC"
        },
        {
          "name": "CYP2D6 Phenotyping",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC",
        "PROCEDURE"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 462,
      "start_date": "2014-09",
      "completion_date": "2017-08-23",
      "has_results": true,
      "last_update_posted_date": "2021-09-16",
      "last_synced_at": "2026-10-29T18:43:52.947Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02293096"
    },
    {
      "nct_id": "NCT05216042",
      "title": "GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Natriuretic Peptides",
        "Cardiometabolic Diseases",
        "Energy Expenditure",
        "Glucose Metabolism",
        "Exercise",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Study diet",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Exercise capacity VO2 max determination",
          "type": "OTHER"
        },
        {
          "name": "Exercise Challenge",
          "type": "OTHER"
        },
        {
          "name": "Glucose Challenge",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2022-04-01",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-29T18:43:52.947Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05216042"
    },
    {
      "nct_id": "NCT06725173",
      "title": "Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinoblastoma Bilateral",
        "Retinoblastoma Unilateral",
        "Retinoblastoma, Extraocular",
        "Retinoblastoma, Recurrent",
        "Retinoblastoma"
      ],
      "interventions": [
        {
          "name": "Targeted Long-read sequencing",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 100,
      "start_date": "2026-03-16",
      "completion_date": "2031-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-18",
      "last_synced_at": "2026-10-29T18:43:52.947Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06725173"
    },
    {
      "nct_id": "NCT01485991",
      "title": "TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "TMC435",
          "type": "DRUG"
        },
        {
          "name": "TVR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen R&D Ireland",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 771,
      "start_date": "2012-02",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2016-04-26",
      "last_synced_at": "2026-10-29T18:43:52.947Z",
      "location_count": 32,
      "location_summary": "Bakersfield, California • San Diego, California • Aurora, Colorado + 29 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01485991"
    }
  ]
}